FOLH1 and prostate carcinoma: Positron emission tomography (PET) radiopharmaceuticals targeting prostate specific membrane antigen (PSMA) receptors on tumor cells can visualize smaller lesions than conventional imaging methods (such as magnetic resonance imaging [MRI] or computed tomography [CT]) [1,2,3], helping to facilitate prostate cancer diagnosis [4] and early detection of recurrent disease [5].